Rockwell Medical Inc (NASDAQ:RMTI) Director Kenneth L. Holt sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $5.98, for a total transaction of $35,880.00. Following the completion of the transaction, the director now directly owns 17,430 shares in the company, valued at $104,231.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Rockwell Medical Inc (NASDAQ:RMTI) traded down 0.17% during trading on Monday, hitting $6.05. 212,114 shares of the stock were exchanged. Rockwell Medical Inc has a 52 week low of $3.55 and a 52 week high of $10.58. The stock’s market cap is $311.74 million. The firm’s 50 day moving average price is $5.94 and its 200-day moving average price is $6.26.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Wednesday, March 15th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The business earned $13.39 million during the quarter, compared to analyst estimates of $15.45 million. Rockwell Medical had a negative net margin of 37.98% and a negative return on equity of 33.60%. The firm’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.12) earnings per share. On average, analysts predict that Rockwell Medical Inc will post ($0.19) EPS for the current year.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/kenneth-l-holt-sells-6000-shares-of-rockwell-medical-inc-rmti-stock.html

Your IP Address:

Separately, Zacks Investment Research cut shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Friday, January 20th.

Several hedge funds have recently bought and sold shares of RMTI. Ladenburg Thalmann Financial Services Inc. boosted its stake in Rockwell Medical by 0.4% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,090 shares of the company’s stock valued at $165,000 after buying an additional 100 shares in the last quarter. Perritt Capital Management Inc. acquired a new stake in Rockwell Medical during the fourth quarter valued at approximately $314,000. State Street Corp boosted its stake in Rockwell Medical by 0.3% in the fourth quarter. State Street Corp now owns 878,759 shares of the company’s stock valued at $5,754,000 after buying an additional 2,523 shares in the last quarter. Cutter & CO Brokerage Inc. acquired a new stake in Rockwell Medical during the fourth quarter valued at approximately $166,000. Finally, Blue Clay Capital Management LLC acquired a new stake in Rockwell Medical during the third quarter valued at approximately $253,000. 21.14% of the stock is owned by institutional investors and hedge funds.

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

5 Day Chart for NASDAQ:RMTI

Receive News & Ratings for Rockwell Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.